cbdMD, Inc. (NYSEAMERICAN:YCBD) Sees Large Drop in Short Interest

cbdMD, Inc. (NYSEAMERICAN:YCBD) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling 752,043 shares, a decrease of 39.1% from the December 31st total of 1,234,477 shares. Currently, 7.3% of the company’s stock are sold short. Based on an average daily trading volume, of 1,242,503 shares, the short-interest ratio is presently 0.6 days. Based on an average daily trading volume, of 1,242,503 shares, the short-interest ratio is presently 0.6 days. Currently, 7.3% of the company’s stock are sold short.

cbdMD Price Performance

NYSEAMERICAN:YCBD traded up $0.27 on Friday, hitting $1.04. The company’s stock had a trading volume of 25,319,015 shares, compared to its average volume of 816,225. cbdMD has a one year low of $0.47 and a one year high of $5.48. The stock has a fifty day moving average of $1.03 and a two-hundred day moving average of $0.93.

Insider Transactions at cbdMD

In other cbdMD news, major shareholder Clark R. Crosnoe sold 550,701 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $2.32, for a total transaction of $1,277,626.32. Following the completion of the transaction, the insider owned 17,875 shares of the company’s stock, valued at $41,470. This represents a 96.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 2.10% of the company’s stock.

About cbdMD

cbdMD, Inc (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.

The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities.